Pluri Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Pluri Inc. (PLUR) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 211.57 thousand shares as of 2026-08-20, per its 10-K filed 2026-09-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2026-09-10
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2023-03-31 was 0.00 shares.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2022-06-30 was 10.00K shares.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 334.82K shares, a 293.91% increase from fiscal 2022.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 85.00K shares, a 22.73% decline from fiscal 2021.
- Pluri Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2021 was 110.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-08-20 | 211.57K shares 10-K · filed 2026-09-10 | |||||
| 2023-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | 0.00 shares derived: sum of 2 quarters · filed 2023-09-12 | 334.82K shares 10-K · filed 2023-09-12 | |||
| 2023-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-09 | 334.82K shares 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | 334.82K shares 10-Q · filed 2024-02-12 | |||||
| 2022-06-30 | 10.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-12 | 85.00K shares 10-K · filed 2023-09-12 | 10.00K shares 10-K · filed 2022-09-21 | |||
| 2022-03-31 | 75.00K shares 10-Q · filed 2023-05-09 | |||||
| 2021-06-30 | 110.00K shares 10-K · filed 2022-09-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |